Basilea Pharmaceutica (XSWX:BSLN) Interest Expense : CHF-11.2 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Basilea Pharmaceutica Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Basilea Pharmaceutica's interest expense for the six months ended in Dec. 2023 was CHF -5.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-11.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Basilea Pharmaceutica's Operating Income for the six months ended in Dec. 2023 was CHF -16.4 Mil. Basilea Pharmaceutica's Interest Expense for the six months ended in Dec. 2023 was CHF -5.4 Mil. Basilea Pharmaceutica did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Basilea Pharmaceutica Interest Expense Historical Data

The historical data trend for Basilea Pharmaceutica's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Interest Expense Chart

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-6.42

-7.59

-8.15

-9.85

-11.20

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-4.02	-3.82	-6.03	-5.80	-5.41

Basilea Pharmaceutica Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-11.2 Mil.

Basilea Pharmaceutica (XSWX:BSLN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Basilea Pharmaceutica's Interest Expense for the six months ended in Dec. 2023 was CHF-5.4 Mil. Its Operating Income for the six months ended in Dec. 2023 was CHF-16.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was CHF111.1 Mil.

Basilea Pharmaceutica's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Basilea Pharmaceutica did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Basilea Pharmaceutica Ltd interest coverage is 1.96, which is low.

Basilea Pharmaceutica (XSWX:BSLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (XSWX:BSLN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BSLNz:UK

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (XSWX:BSLN) Headlines

No Headlines